# reload+after+2024-01-21 00:46:57.257987
address1§4660 La Jolla Village Drive
address2§Suite 100
city§San Diego
state§CA
zip§92122
country§United States
phone§650 800 3717
website§https://www.revbiosciences.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
fullTimeEmployees§6
companyOfficers§[{'maxAge': 1, 'name': 'Mr. James M. Rolke', 'age': 54, 'title': 'CEO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 400000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Chester Stanley Zygmont III', 'age': 43, 'title': 'CFO & Corporate Secretary', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 320000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sandra  Vedrick', 'title': 'Vice President of Human Resources & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Carol  Odle', 'title': 'Senior Director of Clinical Projects', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.398
currency§USD
dateShortInterest§1702598400
forwardEps§-1.54
exchange§NCM
quoteType§EQUITY
shortName§Revelation Biosciences, Inc.
longName§Revelation Biosciences, Inc.
firstTradeDateEpochUtc§1605623400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f994477e-3690-3dde-965e-6f9faa0f03d6
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§7.9
targetMeanPrice§11.45
targetMedianPrice§11.45
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§2.592
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
